Key facts
- This page summarizes Eric Drape's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Mar 2022, 06:45.
Eric Drape - 28 Feb 2022 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
- Reporting relationship
- Executive VP Global Operations
- Issuer ticker
- TEVA
- Reported as of
- 28 Feb 2022
- Net transaction value
- -$79,769
- SEC form
- 4
- Accepted by SEC
- 02 Mar 2022, 06:45:30 UTC
- Prior SEC filing
- 10 Feb 2022
- Next SEC filing
- 08 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dov Bergwerk as attorney-in-fact for Eric Drape
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Drape filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 02 Mar 2022.
Change
- Previous filing in this sequence was filed on 10 Feb 2022.
- Current net transaction value: -$79,769.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TEVA
transaction
Ordinary Shares
Options Exercise
- Transaction value
- Shares
- +19,514
- Change %
- +54%
- Price
- Shares after
- 55,627
- Date
- 28 Feb 2022
- Ownership
- Direct
- Footnotes
- F1, F2
TEVA
transaction
Ordinary Shares
Sale
- Transaction value
- $79,769
- Shares
- -9,797
- Change %
- -18%
- Price
- $8.14
- Shares after
- 45,830
- Date
- 28 Feb 2022
- Ownership
- Direct
- Footnotes
- F1, F3, F4, F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TEVA
transaction
Derivative
Restricted Share Units
Options Exercise
- Transaction value
- $0
- Shares
- -19,514
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 39,029
- Date
- 28 Feb 2022
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 19,514
- Exercise price
- Footnotes
- F1, F2, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Footnote F2
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
Footnote F3
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Footnote F4
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
Footnote F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.035 to $8.255, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Footnote F6
Restricted share units were granted on February 28, 2020, with 19,514 having vested on each of February 28, 2021 and February 28, 2022, 19,514 vesting on February 28, 2023, and 19,515 vesting on February 28, 2024.